Европейски съюз - хърватски - EMA (European Medicines Agency)

intervet international b.v. - svinjske цирковирус tipa 2 (pcv2) podjedinica antigen orf2, микоплазмы hyopneumoniae soja j инактивированная - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinja (za tov) - za aktivne imunizacije svinja za smanjenje виремии, virusne opterećenje u pluća i лимфоидных tkivima, izlučivanje virusa uzrokovana svinjske цирковирус tipa 2 (pcv2) infekcije i težini lezije pluća uzrokovane mycoplasma hyopneumoniae infekcije. kako bi se smanjio gubitak dnevne debljanja tijekom razdoblja završetka u lice infekcija s mycoplasma hyopneumoniae i / ili pcv2 (kao što je vidljivo u terenskim studijama).

Европейски съюз - хърватски - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Европейски съюз - хърватски - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svinje - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - ne više od tri od sljedećih pročišćena, инактивированная noga-i-usta bolest sojeva virusa: o1 manisa ≥ 6 pd50*; o1 БФС ≥ 6 pd50*; oa tajvan 3/97 ≥ 6 pd50*; a22 irak ≥ 6 pd50*; a24 Крузейро ≥ 6 pd50*; turska 14/98 ≥ 6 pd50*; azija-1 Шамир ≥ 6 pd50*; sat2 saudijskoj arabiji ≥ 6 pd50*; * pd50 – 50% sigurnosni prijem u uzgoj, kao što je opisano u filozofiji eura. 0063 monografije. - immunologicals - pigs; cattle; sheep - aktivna imunizacija goveda, ovaca i svinja od 2 tjedna protiv slinavke i šapa radi smanjenja kliničkih znakova.

Европейски съюз - хърватски - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - bluetongue-virus serotype-1 antigen, bluetongue virus serotype 8 antigen - immunologicals - sheep; cattle - sheepactive cijepljenje ovaca i goveda kako bi se spriječilo вирусемии i smanjiti kliničke manifestacije uzrokovane серотипов virusa блютанга 1, 2, 4 i/ ili 8 (kombinacija više od 2 серотипа), aktivna imunizacija ovaca i goveda kako bi se spriječilo вирусемии i za smanjenje kliničkih znakova, uzrokovane virusa блютанга серотипа 1,2, 4 i/ ili 8 (kombinacija maksimalno 2 серотипа), aktivna imunizacija ovaca kako bi se spriječilo вирусемии i smanjiti kliničke manifestacije uzrokovane серотипов virusa блютанга 1, 2, 4 i/ili 8 (kombinacija maksimalno 2 серотипа). cattleactive imunizacija goveda za prevenciju виремии uzrokovane серотипом virusa блютанга 1, 2, 4 i/ ili 8, a za smanjenje kliničkih znakova, uzrokovane virusa блютанга серотипа, kada je došlo kod ove vrste: серотип 1, 4 i / ili 8 (kombinacija maksimalno 2 серотипа). aktivna imunizacija goveda za prevenciju виремии uzrokovane серотипом virusa блютанга 1, 2, 4 i/ ili 8, a za smanjenje kliničkih znakova, uzrokovane virusa блютанга серотипа, kada je došlo kod ove vrste: серотип 1, 4 i / ili 8 (kombinacija maksimalno 2 серотипа). aktivna imunizacija je ovaca i goveda kako bi se spriječilo вирусемии i smanjiti klinički znakovi uzrokovane серотипов virusa блютанга 1, 2, 4 i/ili 8 (kombinacija maksimalno 2 серотипа).

Европейски съюз - хърватски - EMA (European Medicines Agency)

mérial - блютанг-virus серотипа-2 antigena, блютанг-virus серотипа-4 antigena - virus блютанга, инактивированной virusna cjepiva, imunomodulatori za ovidae - ovca - aktivna imunizacija ovaca radi sprječavanja viremije i smanjenja kliničkih znakova uzrokovanih serotipovima 2 i 4 virusa bolesti plavog jezika.